What compounded intranasal spray regimen (e.g., budesonide combined with azelastine) and adjunct therapies are recommended for chronic sinus inflammation that is refractory to standard treatments?

Compound Intranasal Therapy for Refractory Chronic Sinus Inflammation

For chronic sinus inflammation failing standard treatments, use high-volume budesonide nasal irrigations (1 mg budesonide in 500 mL saline daily) as your primary compounded therapy, with consideration for adding intranasal azelastine spray as adjunctive treatment. 1, 2, 3

Primary Compounded Regimen: High-Volume Budesonide Irrigations

The 2025 AAO-HNS guidelines emphasize intranasal corticosteroids and saline irrigation as first-line CRS treatment 1. For refractory disease, high-volume budesonide irrigations deliver superior medication distribution compared to standard sprays:

• Dosing: 1 mg budesonide in 500 mL saline solution, administered daily
• Duration: Minimum 60-90 days for initial trial 3, 4
• Efficacy data: 81.3% of difficult-to-treat CRS patients achieved satisfactory clinical improvement, with significant reductions in SNOT-22 scores (50.2 to 29.6) and Lund-Kennedy endoscopic scores (8.8 to 5.1) 3

Safety Profile

Critical reassurance: High-dose, high-volume budesonide irrigations do not cause HPA axis suppression even with long-term use 2, 4. Studies using ACTH stimulation testing found no adrenal suppression and no detectable plasma budesonide levels, confirming the safety of this approach for extended therapy 4. This addresses a common concern that inappropriately limits aggressive topical corticosteroid use.

Adjunctive Intranasal Azelastine

Add intranasal azelastine (137 mcg per spray, 2 sprays per nostril twice daily) when allergic or inflammatory components persist despite budesonide therapy 5, 6:

• Provides H1-receptor antagonism with anti-inflammatory effects beyond antihistamine action
• Recent 2026 data shows 56.6% reduction in acute exacerbation episodes when used prophylactically 6
• Works synergistically with corticosteroids by addressing different inflammatory pathways
• FDA-approved dosing: 2 sprays per nostril twice daily (total 548 mcg/day) 5

What NOT to Do

Do not routinely prescribe prolonged courses of oral antibiotics (4-6 weeks) for refractory CRS without acute bacterial exacerbation 1. The 2025 guidelines explicitly recommend against this outdated practice:

• CRS is primarily inflammatory, not infectious
• Randomized trials show no benefit from doxycycline compared to topical budesonide or oral steroids 1
• Antibiotic use contributes to resistance without improving outcomes
• Exception: Odontogenic sinusitis or documented acute bacterial superinfection

Do not require a "one-size-fits-all" medication regimen before considering surgery 7. The term "appropriate medical therapy" has replaced "maximal medical therapy" because:

• No consensus exists on what constitutes "maximal" therapy
• Continuing ineffective treatments causes harm through side effects and delayed definitive care
• Patient tolerance and disease subtype should guide therapy duration

Alternative Delivery Methods

If high-volume irrigations are not tolerated, mucosal atomization devices (MAD) provide effective budesonide delivery with comparable safety 4:

• 1 mg budesonide twice daily via MAD
• Atomizes medication into small droplets for enhanced sinus penetration
• No HPA axis suppression detected in 60-day trials
• Significant SNOT-22 improvement at 60 days

When to Escalate

Consider surgical intervention or biologics when:

• Adequate trial of high-volume budesonide irrigations (90+ days) fails to achieve acceptable symptom control
• Quality of life remains significantly impaired despite optimized topical therapy
• Recurrent acute exacerbations continue despite prophylactic measures
• Structural abnormalities prevent medication delivery

The 2025 guidelines emphasize that biologics should only be considered after optimizing conventional topical therapies, given their high cost and the robust effectiveness of properly administered intranasal corticosteroids 1.

Practical Implementation Algorithm

1. Initiate: High-volume budesonide irrigations (1 mg in 500 mL saline daily)
2. Add at 2-4 weeks if inadequate response: Intranasal azelastine (2 sprays per nostril twice daily)
3. Reassess at 90 days: Measure SNOT-22 scores and perform nasal endoscopy
4. If improved: Continue therapy with periodic monitoring
5. If refractory: Consider surgical evaluation or biologic therapy, not prolonged antibiotics

This approach prioritizes evidence-based topical anti-inflammatory therapy while avoiding the pitfalls of unnecessary antibiotic use and premature escalation to costly systemic treatments.